EPO Protein (AA 28-193) (His tag)

N° du produit ABIN7505129

Détail du produit

Antigène: EPO (Erythropoietin (EPO))

Type de proteíne: Recombinant

Attributs du protein: AA 28-193

Origine: Humain

Source: Escherichia coli (E. coli)

Purification/Conjugué: Cette EPO protéine est marqué à la His tag.

Séquence: Ala 28-Arg 193

Attributs du produit: A DNA sequence encoding the Human EPO protein (P01588) (Ala 28-Arg 193) was expressed with a C-His tag.

Pureté: > 95 % as determined by reducing SDS-PAGE.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Date de péremption: 12 months

Détail du antigène

Antigène: EPO (Erythropoietin (EPO))

Autre désignation: EPO (EPO Produits)

Synonymes: EPO Protein, EP Protein, MVCD2 Protein, erythropoietin Protein, erythropoietin S homeolog Protein, erythropoietin a Protein, EPO Protein, epo Protein, epo.S Protein, Epo Protein, epoa Protein

Classe de substances: Hormone

Sujet:

Abbreviation: EPO

Target Synonym: Epoetin,EPO,Erythropoietin

Background: Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin. Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species. Glycosylation of the EPO protein is required for biological activities in vivo. The mature human EPO protein shares 75 % - 84 % amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules. It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain. EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the erythropoietin receptor (EPO R). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells. Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation. Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce erythropoietin production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha. EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis.

Poids moléculaire:

Calculated MW: 18.15 kDa

Observed MW: 20 kDa

UniProt: P01588

Pathways: Signalistation JAK/STAT, Hormone Activity, Negative Regulation of intrinsic apoptotic Signaling, Negative Regulation of Transporter Activity